title: Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: a meta-analysis.
abstract: OBJECTIVE
  Neutropenia is a serious adverse event for patients who are treated with cetuximab, an inhibitor of endothelial growth factor receptor. However, there is no consistent result of the relationship between cetuximab and neutropenia in randomized controlled trials (RCTs). We did a systematic review and meta-analysis of published RCTs to assess the overall risk of neutropenia associated with cetuximab.
  
  
  METHODS
  PubMed, Cochrane Central Register of Controlled Trials, EMBASE, and American Society of Clinical Oncology conferences were searched for relevant RCTs. Quantitative and qualitative analyses were carried out to evaluate the association between neutropenia and cetuximab. Both the fixed-effect model and random-effects model were used.
  
  
  RESULTS
  A total of 7186 patients with a variety of advanced cancers from 14 trials were included in our analysis. The overall incidence of neutropenia in patients receiving cetuximab was 33% (95% CI 26, 43). Patients treated with cetuximab had a significantly increased risk of neutropenia compared with patients treated with control medication, with a relative risk (RR) of 1.12 (95% CI 1.05, 1.19; fixed-effect model). Risk varied with tumor type. Higher risks were observed in patients with colorectal carcinoma (RR 1.17; 95% CI 1.04, 1.32; fixed-effect model) and non-small cell lung cancer (RR 1.07; 95% CI 0.99, 1.16; fixed-effect model).
  
  
  CONCLUSIONS
  Cetuximab is associated with a significant risk of neutropenia in patients with advanced cancer receiving concurrent chemotherapy.
authors: Company of Anesthesiology, Second Military Medical University, Shanghai, Peoples Republic of China.
authors: Long
authors: L
authors: Wang
authors: Yi-Zhi
authors: YZ
authors: Chen
authors: Duo
authors: D
authors: Shi
authors: Xue-Yin
authors: XY
authors: Shi
authors: Zui
authors: Z
authors: Zou
authors: Jian-Hua
authors: JH
authors: Zhao
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects; D000068818:Cetuximab; D006801:Humans; D015994:Incidence; D009369:Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D009503:Neutropenia / Q000139:chemically induced* / Q000453:epidemiology* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D012720:Severity of Illness Index
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab